Atlas Trials

A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Clinical trial NCT05619692 · COMPLETED

Trial details

NCT number
NCT05619692
Sponsor
Supernus Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Mild Cognitive ImpairmentMild DementiaAlzheimer's Disease
Start date
2022-11-29
Primary completion
2024-06-05
Enrollment
174

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.